ClinicalTrials.gg
CompletedNCT01884350AEGEANUpdated Aug 19, 2019Results posted

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)

A Phase 4 interventional study of Apixaban in Non-valvular Atrial Fibrillation, sponsored by Bristol-Myers Squibb. Completed at 223 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-19.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,217
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing apixaban in Atrial Fibrillation — 11 open to participants now, 12 under way, 4 of them phase 3. apixaban · Atrial Fibrillation.

Enrollment
9th of 31
1,217 · median 586
Started
2013
the only one that year
Phase 4
14 of 31
6 open now
Registered
4th of 31
by date
Lead sponsor
3 of 31
Bristol-Myers Squibb

Among the 31 studies testing apixaban in Atrial Fibrillation, this one is the 9th largest by enrollment, is the only one that started in 2013, is one of 14 in phase 4, and was the 4th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

11 of the 31 studies testing apixaban in Atrial Fibrillation are open now, in 10 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing apixaban in Atrial Fibrillation, or all of them as a file.
02

Study summary

The study purpose is to assess the impact of an educational program on patient adherence in patients taking Apixaban for SPAF at 24 weeks

Read the detailed description

SPAF=Stroke Prevention in Atrial Fibrillation

ISTH=International Society on Thrombosis and Hemostasis

Primary Purpose: Other: To measure adherence to the study medication using an electronic monitoring device over the first 24 weeks on study medication

03

Conditions studied

  • Non-valvular Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with diagnosed non-valvular Atrial Fibrillation (AF) or atrial flutter (documented by 12-lead (ECG) or Holter recording) and eligible for oral anticoagulant (OAC) therapy
  2. Presence of at least one of the following risk factors for stroke:

    Prior stroke or (TIA)

    • Age ≥75 years
    • Hypertension
    • Diabetes mellitus
    • Symptomatic heart failure [ (NYHA) Class ≥II]
  3. Must be able to self-administer treatment
  4. Either Vitamin K antagonists (VKA) treated or VKA naive. Patients treated with VKA should have received the VKA treatment for ≥3 months. VKA naïve patients should not have received VKA treatment for more than 30 days within the last 12 months. Patients who are not described by either of the above criteria are not eligible for the study
  5. Patients previously treated with acetylsalicylic acid (ASA) for stroke prevention are allowed (and will switch to Apixaban)
  6. Patients with screening (MMSE) more than 24
  7. Subject Re-enrollment: This study does not permit the re-enrollment of a subject that has discontinued the study as a pre-treatment failure

Age and Reproductive Status:

  • i) Men and women ≥18 years of age
  • ii) Women of (WOCBP) must use method(s) of based on the tables in protocol. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study medication
  • iv) Women must not be breastfeeding
  • v) Men who are sexually active with women of childbearing potential (WOCBP) must use any contraceptive method with a failure rate of less than 1% per year
  • vi) Women who are not of childbearing potential (ie, who are or surgically sterile); and azoospermic men do not require contraception

Exclusion criteria

Exclusion Criteria:

  1. Target Disease Exceptions:

    1. Atrial fibrillation or flutter due to reversible causes (e.g. thyrotoxicosis, pericarditis)
    2. (moderate or severe) mitral stenosis
    3. Cardiac valvular disease requiring surgery
    4. Planned major surgery or/and invasive procedure and/or atrial fibrillation or flutter, ablation procedure and/or cardioversion
    5. Patients receiving Rivaroxaban, Dabigatran or Apixaban
  2. Medical History and Concurrent Diseases:

    1. Conditions other than atrial fibrillation that require chronic anticoagulation (e.g., prosthetic mechanical heart valve, venous thromboembolism; also see Section 3.4, Concomitant Treatments)
    2. Patient with serious bleeding in the last 6 months or with a lesion or condition at high risk of bleeding such as:

      • Active peptic ulcer disease, current or recent gastrointestinal ulceration
      • Known or suspected esophageal varices
      • Recent ischemic stroke (within 7 days)
      • Recent brain or spinal injury or intracranial hemorrhage
      • Recent brain, spinal or ophthalmic surgery
      • Arteriovenous malformations
      • Vascular aneurysms
      • Major intraspinal or intracerebral vascular abnormalities
      • Documented hemorrhagic tendencies or blood dyscrasias
      • Presence of malignant neoplasms at high risk of bleeding
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,217 participants (actual)

Study arms

  • Experimental
    Arm 1: Apixaban (Primary SOC information)

    Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Primary Standard of Care (SOC) information

    Drug: Apixaban

  • Experimental
    Arm 2: Apixaban (Additional Educational Program)

    Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Additional Educational Program

    Drug: Apixaban

Interventions

  • Also known as: Eliquis, BMS-562247

06

What researchers measure

Primary outcomes

  1. Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen

    The mean percentage of days which participants maintained adherence to apixaban treatment was measured for each arm. Adherence to apixaban = number of units of adherence \*100 / total number of eligible days for the time period from first dose date, up to 169 days. Unit of adherence: A 24-hour window where the treatment is taken as prescribed, ie, 1 tablet (5 mg or 2.5 mg, as appropriate) 2 times a day. If only one dose is missed in 24-hours, it is still considered as a unit of adherence. Adherence up to 24 weeks was calculated as the percentage of adherence units within that period. If a participant discontinued from the study before 24 weeks, the denominator time period was censored at the earlier of last dose date or discontinuation date for discontinuation due to reasons unrelated to participant adherence, such as withdrawn consent, or AE; otherwise, the period was censored at the minimum of 169 days and last dose date + 30 days.

    Time frame: Day 1 up to week 24

Secondary outcomes

  1. Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 12 to 24 Weeks Period Compared With During the First 12 Weeks

    The mean adherence to apixaban treatment during the first 24 weeks was measured between the standard of care (SOC) information and Additional Education Program (AEP) arms and expressed as a percentage. Adherence to Apixaban = number of units of adherence \*100 / total number of eligible days for the time period.

    Time frame: Day 1 to Week 12, Week 12 to Week 24

  2. Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 24 to 48 Weeks Period

    The mean percentage of days which participants maintained adherence to apixaban treatment was measured for each arm. Adherence to apixaban = number of units of adherence \*100 / total number of eligible days for the time period from first dose date, up to 169 days. Unit of adherence: A 24-hour window where the treatment is taken as prescribed, ie, 1 tablet (5 mg or 2.5 mg, as appropriate) 2 times a day. If only one dose is missed in 24-hours, it is still considered as a unit of adherence. Adherence over 24 weeks was calculated as the percentage of adherence units within that period. If a participant discontinued from the study before 48 weeks, the denominator time period was censored at the earlier of last dose date or discontinuation date for discontinuation due to reasons unrelated to participant adherence, such as withdrawn consent, or AE; otherwise, the period was censored at the minimum of 169 days and last dose date + 30 days.

    Time frame: Week 24 to Week 48

  3. Non-adherence Predictors of 20% or More (vs. at Least 80% Adherence) at 24 Weeks

    Logit analyses were conducted on the Primary Efficacy Set to identify non-adherence predictors of 20% or more (vs. at least 80% adherence) at 24 weeks. In the Primary SOC group, alcohol use, Mini-Mental State Evaluation (MMSE) score, UK standard occupational classification, and type of atrial fibrillation were retained in the model (p-value \<= 0.2). In the Additional Educational Program group, alcohol use, type of atrial fibrillation, age and Vitamin K Antagonists (VKA) status were retained in the model (p-value \<= 0.2). Odds ratios are presented for predictors of non-adherence.

    Time frame: Week 24

  4. Number of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AE), AE Leading to Discontinuation, and Death

    AEs with onset date from day 1 through week 24 are included in this summary. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

    Time frame: Day 1 up to week 24

  5. Number of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AE), AE Leading to Discontinuation, and Death

    Adverse events with onset date after 24 weeks are included in this summary. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

    Time frame: Week 24 up to Week 48

07

Results

Posted Aug 19, 2019

Participant flow

Primary Efficacy Analysis Set (24 Weeks)
Participant flow — Primary Efficacy Analysis Set (24 Weeks)
MilestoneApixaban (Primary SOC)Apixaban (Additional Educational Program)Apixaban (Secondary SOC)
Started5835790
Safety analysis set6045580
Completed5295250
Not completed54540
Withdrew: Subject withdrew consent17200
Withdrew: Death640
Withdrew: Lost to follow-up010
Withdrew: Serious adverse event760
Withdrew: Adverse event15110
Withdrew: Drug interruption >30 consecutive days020
Withdrew: Inclusion/exclusion criterion250
Withdrew: Helping hand not used200
Withdrew: Helping hand not used, treatment taken110
Withdrew: Withdrawal by subject110
Withdrew: Medical reason330
Primary Efficacy Analysis Set (48 Weeks)
Participant flow — Primary Efficacy Analysis Set (48 Weeks)
MilestoneApixaban (Primary SOC)Apixaban (Additional Educational Program)Apixaban (Secondary SOC)
Started583263261
Safety analysis set604308223
Completed503250250
Not completed801311
Withdrew: Subject withdrew consent2102
Withdrew: Death733
Withdrew: Lost to follow-up101
Withdrew: Serious adverse event1763
Withdrew: Adverse event1730
Withdrew: Drug interruption >30 consecutive days302
Withdrew: Helping hand not used400
Withdrew: Helping hand not used, treatment taken300
Withdrew: Medical reason410
Withdrew: Subject decision100
Withdrew: Inclusion / exclusion criterion200

Outcome measures

PrimaryPercentage of Days With a Correct Execution of the Apixaban Dosing Regimen

The mean percentage of days which participants maintained adherence to apixaban treatment was measured for each arm. Adherence to apixaban = number of units of adherence \*100 / total number of eligible days for the time period from first dose date, up to 169 days. Unit of adherence: A 24-hour window where the treatment is taken as prescribed, ie, 1 tablet (5 mg or 2.5 mg, as appropriate) 2 times a day. If only one dose is missed in 24-hours, it is still considered as a unit of adherence. Adherence up to 24 weeks was calculated as the percentage of adherence units within that period. If a participant discontinued from the study before 24 weeks, the denominator time period was censored at the earlier of last dose date or discontinuation date for discontinuation due to reasons unrelated to participant adherence, such as withdrawn consent, or AE; otherwise, the period was censored at the minimum of 169 days and last dose date + 30 days.

Time frame:
Day 1 up to week 24
Reported as:
Mean · percentage of days
Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen
percentage of daysApixaban (Primary SOC Information)Apixaban (Additional Educational Program)
Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen91.64 ± 17.14391.88 ± 16.140
Statistical analysis
  • Apixaban (Primary SOC Information) vs Apixaban (Additional Educational Program) · t-test, 2 sided · p = 0.8117 (P-value (two-sided) corresponds to the two-sample t-tests for difference in percentage of adherence at Week 24) · Difference in percentage: -0.24 · 95% CI -2.18 to 1.7
SecondaryPercentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 12 to 24 Weeks Period Compared With During the First 12 Weeks

The mean adherence to apixaban treatment during the first 24 weeks was measured between the standard of care (SOC) information and Additional Education Program (AEP) arms and expressed as a percentage. Adherence to Apixaban = number of units of adherence \*100 / total number of eligible days for the time period.

Time frame:
Day 1 to Week 12, Week 12 to Week 24
Reported as:
Mean · percentage
Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 12 to 24 Weeks Period Compared With During the First 12 Weeks
percentageApixaban (Primary SOC Information)Apixaban (Additional Educational Program)
Day 1 to Week 1293.7 ± 14.1893.0 ± 15.71
Week 12 to Week 2490.3 ± 20.6490.9 ± 18.36
Statistical analysis
  • Apixaban (Primary SOC Information) · paired t-test · p = <0.0001 (P-value is from a paired t-test comparing percent adherence at 12 and 24 Weeks. Only participants with available data at both Study Days 85 and 169 are included.)
  • Apixaban (Additional Educational Program) · paired t-test · p = <0.0001 (P-value is from a paired t-test comparing percent adherence at 12 and 24 Weeks. Only participants with available data at both Study Days 85 and 169 are included.)
SecondaryPercentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 24 to 48 Weeks Period

The mean percentage of days which participants maintained adherence to apixaban treatment was measured for each arm. Adherence to apixaban = number of units of adherence \*100 / total number of eligible days for the time period from first dose date, up to 169 days. Unit of adherence: A 24-hour window where the treatment is taken as prescribed, ie, 1 tablet (5 mg or 2.5 mg, as appropriate) 2 times a day. If only one dose is missed in 24-hours, it is still considered as a unit of adherence. Adherence over 24 weeks was calculated as the percentage of adherence units within that period. If a participant discontinued from the study before 48 weeks, the denominator time period was censored at the earlier of last dose date or discontinuation date for discontinuation due to reasons unrelated to participant adherence, such as withdrawn consent, or AE; otherwise, the period was censored at the minimum of 169 days and last dose date + 30 days.

Time frame:
Week 24 to Week 48
Reported as:
Mean · percentage
Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 24 to 48 Weeks Period
percentageApixaban (Primary SOC Information)Apixaban (Additional Educational Program)Apixaban (Secondary SOC)
Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 24 to 48 Weeks Period87.59 ± 22.92188.41 ± 22.14887.51 ± 21.125
Statistical analysis
  • Apixaban (Primary SOC Information) vs Apixaban (Additional Educational Program) vs Apixaban (Secondary SOC) · ANOVA · p = 0.8707
  • Apixaban (Additional Educational Program) vs Apixaban (Secondary SOC) · t-test, 2 sided · p = 0.6399 (P-values are obtained from the Cochran t-test for pairwise comparison between groups (two-sided).) · Mean difference (final values): 0.90 · 95% CI -2.88 to 4.68
  • Apixaban (Primary SOC Information) vs Apixaban (Secondary SOC) · t-test, 2 sided · p = 0.9616 (P-values are obtained from the Cochran t-test for pairwise comparison between groups (two-sided).) · Mean difference (final values): -0.08 · 95% CI -3.45 to 3.29
  • Apixaban (Primary SOC Information) vs Apixaban (Additional Educational Program) · t-test, 2 sided · p = 0.6341 (P-values are obtained from the Cochran t-test for pairwise comparison between groups (two-sided).) · Mean difference (final values): 0.82 · 95% CI -2.60 to 4.24
SecondaryNon-adherence Predictors of 20% or More (vs. at Least 80% Adherence) at 24 Weeks

Logit analyses were conducted on the Primary Efficacy Set to identify non-adherence predictors of 20% or more (vs. at least 80% adherence) at 24 weeks. In the Primary SOC group, alcohol use, Mini-Mental State Evaluation (MMSE) score, UK standard occupational classification, and type of atrial fibrillation were retained in the model (p-value \<= 0.2). In the Additional Educational Program group, alcohol use, type of atrial fibrillation, age and Vitamin K Antagonists (VKA) status were retained in the model (p-value \<= 0.2). Odds ratios are presented for predictors of non-adherence.

Time frame:
Week 24
Reported as:
Number · Odds ratio
Non-adherence Predictors of 20% or More (vs. at Least 80% Adherence) at 24 Weeks
Odds ratioApixaban (Primary SOC Information)Apixaban (Additional Educational Program)
<=2 Alcoholic Drink/Day Average vs None1.251 (0.691 to 2.265)0.994 (0.558 to 1.682)
>=3 Alcoholic Drink/Day Average vs None4.268 (1.226 to 14.859)3.782 (0.884 to 16.178)
Mini-mental state examination score0.808 (0.686 to 0.952)NA (NA to NA)
Higher mgmt., adm. and professional jobs vs UKSOC10.827 (0.136 to 5.033)NA (NA to NA)
Higher professional occupations vs UKSOC10.898 (0.197 to 4.091)NA (NA to NA)
Intermediate occupations vs UKSOC11.230 (0.401 to 3.769)NA (NA to NA)
Large employers and mgmt. and adm. jobs vs UKSOC12.823 (0.412 to 19.338)NA (NA to NA)
Lower mgmt., adm. and professional jobs vs UKSOC10.948 (0.256 to 3.515)NA (NA to NA)
Lower supervisory and tech. occupations vs UKSOC13.587 (1.008 to 12.766)NA (NA to NA)
Never worked and long-term unemployed vs UKSOC11.289 (0.419 to 3.962)NA (NA to NA)
Routine occupations vs UKSOC10.508 (0.181 to 1.425)NA (NA to NA)
Semi-routine occupations vs UKSOC10.450 (0.083 to 2.453)NA (NA to NA)
Paroxysmal vs Persistant Atrial Fibrillation1.626 (0.766 to 3.453)1.911 (0.940 to 3.885)
Permanent vs Persistant Atrial Fibrillation2.560 (1.152 to 5.688)1.846 (0.819 to 4.158)
VKA Naïve vs Non-NaïveNA (NA to NA)1.686 (0.932 to 3.049)
Statistical analysis
  • Apixaban (Primary SOC Information) · Wald Chi-square test · p = 0.1924 (\<=2 Drink/Day Average vs None)
  • Apixaban (Primary SOC Information) · Wald Chi-square test · p = 0.0305 (\>=3 Drink/Day Average vs None)
  • Apixaban (Primary SOC Information) · Wald Chi-square test · p = 0.0107 (Mini-mental state examination score)
  • Apixaban (Primary SOC Information) · Wald Chi-square test · p = 0.6982 (Higher managerial, administrative and professional occupations vs UKSOC1)
  • Apixaban (Primary SOC Information) · Wald Chi-square test · p = 0.7277 (Higher professional occupations vs UKSOC1)
  • Apixaban (Primary SOC Information) · Wald Chi-square test · p = 0.7581 (Intermediate occupations vs UKSOC1)
  • Apixaban (Primary SOC Information) · Wald Chi-square test · p = 0.2328 (Large employers and higher managerial and adm. occupations vs UKSOC1)
  • Apixaban (Primary SOC Information) · Wald Chi-square test · p = 0.7507 (Lower managerial, administrative and professional occupations vs UKSOC1)
  • Apixaban (Primary SOC Information) · Wald Chi-square test · p = 0.0091 (Lower supervisory and technical occupations vs UKSOC1)
  • Apixaban (Primary SOC Information) · Wald Chi-square test · p = 0.6730 (Never worked and long-term unemployed vs UKSOC1)
  • Apixaban (Primary SOC Information) · Wald Chi-square test · p = 0.0117 (Routine occupations vs UKSOC1)
  • Apixaban (Primary SOC Information) · Wald Chi-square test · p = 0.1910 (Semi-routine occupations vs UKSOC1)
  • Apixaban (Primary SOC Information) · Wald Chi-square test · p = 0.9559 (Paroxysmal vs Persistent Atrial Fibrillation)
  • Apixaban (Primary SOC Information) · Wald Chi-square test · p = 0.0264 (Permanent vs Persistant Atrial Fibrillation)
  • Apixaban (Additional Educational Program) · Wald Chi-square test · p = 0.1087 (\<=2 Drink/Day Average vs None)
  • Apixaban (Additional Educational Program) · Wald Chi-square test · p = 0.0679 (\>=3 Drink/Day Average vs None)
  • Apixaban (Additional Educational Program) · Wald Chi-square test · p = 0.2128 (Paroxysmal vs Persistant Atrial Fibrillation)
  • Apixaban (Additional Educational Program) · Wald Chi-square test · p = 0.3739 (Permanent vs Persistant Atrial Fibrillation)
  • Apixaban (Additional Educational Program) · Wald Chi-square test · p = 0.843 (VKA status: Naive vs. Non-Naive)
SecondaryNumber of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AE), AE Leading to Discontinuation, and Death

AEs with onset date from day 1 through week 24 are included in this summary. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

Time frame:
Day 1 up to week 24
Reported as:
Number · Participants
Number of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AE), AE Leading to Discontinuation, and Death
ParticipantsApixaban (Primary SOC Information)Apixaban (Additional Educational Program)
SAE7582
Drug related AE5441
AE leading to discontinuation3322
Death65
SecondaryNumber of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AE), AE Leading to Discontinuation, and Death

Adverse events with onset date after 24 weeks are included in this summary. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

Time frame:
Week 24 up to Week 48
Reported as:
Number · Participants
Number of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AE), AE Leading to Discontinuation, and Death
ParticipantsApixaban (Primary SOC Information)Apixaban (Additional Educational Program)Apixaban (Secondary SOC)
SAE714330
Drug related AE151210
AE leading to discontinuation1438
Death336

Adverse events

Collected over From date of first dose to date of last dose plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Primary SOC (Period 1)—69/604 (11.4%)40/604 (6.6%)
Continued Additional Educational Program (CAEP) (Period 2)—40/308 (13%)5/308 (1.6%)
Secondary SOC (Period 2)—29/223 (13%)5/223 (2.2%)
Additional Educational Program (Period 1)—79/558 (14.2%)46/558 (8.2%)
Primary SOC (Period 2)—62/604 (10.3%)21/604 (3.5%)
Most frequent serious events
Showing 10 of 230
Most frequent serious events
EventPrimary SOC (Period 1)Continued Additional Educational Program (CAEP) (Period 2)Secondary SOC (Period 2)Additional Educational Program (Period 1)Primary SOC (Period 2)
Cardiac failureCardiac disorders9/6043/3081/22313/5584/604
Atrial fibrillationCardiac disorders7/6040/3081/22310/5583/604
Cardiac ablationSurgical and medical procedures8/6041/3080/2233/5583/604
Myocardial infarctionCardiac disorders0/6040/3082/2232/5580/604
DyspnoeaRespiratory, thoracic and mediastinal disorders0/6041/3082/2234/5581/604
PneumoniaInfections and infestations5/6041/3082/2233/5582/604
HypertensionVascular disorders1/6042/3080/2230/5581/604
Angina pectorisCardiac disorders1/6042/3081/2232/5580/604
Chronic obstructive pulmonaryRespiratory, thoracic and mediastinal disorders1/6042/3080/2231/5581/604
Infective exacerbation of chronic obstructive airways diseaseInfections and infestations0/6042/3080/2230/5581/604
Most frequent other events
Most frequent other events
EventPrimary SOC (Period 1)Continued Additional Educational Program (CAEP) (Period 2)Secondary SOC (Period 2)Additional Educational Program (Period 1)Primary SOC (Period 2)
DyspnoeaRespiratory, thoracic and mediastinal disorders40/6045/3085/22346/55821/604

Baseline characteristics

Primary Efficacy Analysis Set (24 week)

Age, Continuous
Age, Continuous(years)Apixaban (Primary SOC Information)Apixaban (Additional Educational Program)Total
Mean72.6 ± 8.9473.1 ± 9.0572.9 ± 9.00
Age, Customized
Age, Customized(Participants)Apixaban (Primary SOC Information)Apixaban (Additional Educational Program)Total
<64 years8677163
64-74 years221220441
>=75 years276282558
Sex: Female, Male
Sex: Female, Male(Participants)Apixaban (Primary SOC Information)Apixaban (Additional Educational Program)Total
Female232234466
Male351345696
08

Study locations

223 sites
  • Local Institution
    Antwerpen, 2060, Belgium
  • Local Institution
    Arlon, 6700, Belgium
  • Local Institution
    Bonheiden, 2820, Belgium
  • Local Institution
    Braine-l'alleud, 1420, Belgium
  • Local Institution
    Brussels, 1090, Belgium
  • Local Institution
    Bruxelles, 1020, Belgium
  • Local Institution
    Gent, 9000, Belgium
  • Local Institution
    Gilly, 6060, Belgium
  • Local Institution
    Hasselt, 3500, Belgium
  • Local Institution
    Leuven, 3000, Belgium
  • Local Institution
    Liege, 4000, Belgium
  • Local Institution
    Ronse, 9600, Belgium
  • Local Institution
    Woluwe- Saint Lambert, 1200, Belgium
  • Local Institution
    Yvoir, 5530, Belgium
  • Local Institution
    Yvoir, B-5530, Belgium
  • Local Institution
    Saint Etienne, Cedex 2 42055, France
  • Local Institution
    Abbeville, 80142, France
  • Local Institution
    Aix En Provence, 13616, France
  • Local Institution
    Avignon Cedex 9, 84902, France
  • Local Institution
    Avignon, 84000, France
  • Local Institution
    Bayonne Cedex, 64109, France
  • Local Institution
    Bayonne, 64100, France
  • Local Institution
    Beziers Cedex, 34525, France
  • Local Institution
    Bobigny, 93009, France
  • Local Institution
    Bordeaux, 33000, France
  • Local Institution
    Bordeaux, 33075, France
  • Local Institution
    Boulogne-billancourt, 92100, France
  • Local Institution
    Brest, 29609, France
  • Local Institution
    Bron, 69677, France
  • Local Institution
    Caen, 14000, France
  • Local Institution
    Cambrai, 59407, France
  • Local Institution
    Cannes, 06400, France
  • Local Institution
    Chambray-les- Tours, 37044, France
  • Local Institution
    Chartes, 28108, France
  • Local Institution
    Chatellerault, 86106, France
  • Local Institution
    Cholet, 49309, France
  • Local Institution
    Clermont Ferrand, 63003, France
  • Local Institution
    Colombes, 92701, France
  • Local Institution
    Corbeil Essonnes, 91106, France
  • Local Institution
    Creteil Cedex, 94010, France
  • Local Institution
    Dijon Cedex, 21079, France
  • Local Institution
    Grenoble Cedex 09, 38043, France
  • Local Institution
    Grenoble Cedex 9, 38043, France
  • Local Institution
    Haguenau Cedex, 67502, France
  • Local Institution
    La Rochelle Cedex, 17019, France
  • Local Institution
    Le Chesnay, 78150, France
  • Local Institution
    Lille Cedex, 59037, France
  • Local Institution
    Lille, 59000, France
  • Local Institution
    Longjumeau, 91164, France
  • Local Institution
    Marseille Cedex 20, 13915, France
  • Local Institution
    Marseille, 13003, France
  • Local Institution
    Marseille, 13008, France
  • Local Institution
    Marseille, 13385, France
  • Local Institution
    Montfermeil, 93370, France
  • Local Institution
    Montpellier, 34000, France
  • Local Institution
    Montpellier, 34295, France
  • Local Institution
    Nantes Cedex 2, 44277, France
  • Local Institution
    Neuilly Sur Seine, 92523, France
  • Local Institution
    Nice, 06105, France
  • Local Institution
    Nimes Cedex 9, 30029, France
  • Local Institution
    Orleans Cedex 2, 45067, France
  • Local Institution
    Paris Cedex 14, 75674, France
  • Local Institution
    Paris Cedex, 75013, France
  • Local Institution
    Paris, 75010, France
  • Local Institution
    Paris, 75013, France
  • Local Institution
    Paris, 75015, France
  • Local Institution
    Paris, 75908, France
  • Local Institution
    Pau Universite Cedex, 64046, France
  • Local Institution
    Pessac, 33604, France
  • Local Institution
    Plan de Cuques, 13380, France
  • Local Institution
    Rennes Cedex 9, 35033, France
  • Local Institution
    Saint Denis, 93207, France
  • Local Institution
    Salouel, 80480, France
  • Local Institution
    Sete, 34200, France
  • Local Institution
    St. Benoit, 86280, France
  • Local Institution
    Strasbourg, 67000, France
  • Local Institution
    Strasbourg, 67090, France
  • Local Institution
    Thionville, 57100, France
  • Local Institution
    Thonon Les Bains, 74203, France
  • Local Institution
    Toulouse Cedex 3, 31076, France
  • Local Institution
    Toulouse, 31054, France
  • Local Institution
    Tourcoing, 59208, France
  • Local Institution
    Valence, 26000, France
  • Local Institution
    Valenciennes Cedex, 59322, France
  • Local Institution
    Vesoul, 70014, France
  • Local Institution
    Wardenburg, 26203, France
  • Local Institution
    Spaichingen, Baden-wurttembe 78549, Germany
  • Local Institution
    Krombach, Bayern 63829, Germany
  • Local Institution
    Augsburg, 86159, Germany
  • Local Institution
    Aurich, 26603, Germany
  • Local Institution
    Bad Homburg, 61348, Germany
  • Local Institution
    Balingen, 72336, Germany
  • Local Institution
    Bamberg, Germany
  • Local Institution
    Berin, 10559, Germany
  • Local Institution
    Berlin, 10367, Germany
  • Local Institution
    Berlin, 10789, Germany
  • Local Institution
    Berlin, 12351, Germany
  • Local Institution
    Berlin, 12524, Germany
  • Local Institution
    Berlin, 13405, Germany
  • Local Institution
    Chemnitz, 09122, Germany

Showing the first 100 of 223 sites across 7 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Montalescot G, Brotons C, Cosyns B, Crijns HJ, D'Angelo A, Drouet L, Eberli F, Lane DA, Besse B, Chan A, Vicaut E, Darius H; AEGEAN Study Investigators. Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial. Am J Cardiovasc Drugs. 2020 Feb;20(1):61-71. doi: 10.1007/s40256-019-00356-2. PubMed 31243691 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Jan 2016, 27 months.

Results were first posted in Aug 2019, 3 years 6 months after primary completion.

Of 141 phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 81. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2013
First posted
Jun 24, 2013
StartActual
Oct 15, 2013
Primary completionActual
Jan 20, 2016
CompletionActual
Jan 20, 2016
Results first posted
Aug 19, 2019
Last update
Aug 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01884350
Responsible party
Sponsor
First posted
Jun 24, 2013
Start date
Oct 15, 2013
Primary completion
Jan 20, 2016
Completion
Jan 20, 2016
Results posted
Aug 19, 2019
Last update
Aug 19, 2019

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion